Product
CAR Target
mAb Combination
First Indications
IND
––––––––
CD20 / rituximab
First Indications
Q3 2020
HER2
Potentially anti-PD-L1
2nd line HER2+ Gastric Cancer
1H 2021
CD19
anti-CD20
B-cell Malignancies
2H 2021
Not Disclosed
Not Disclosed
T-cell lymphomas or leukemias
TBD
NK-related target
Potentially anti-PD-L1
Advanced NSCLC
TBD
Allogeneic Cord-Blood Derived NK-Cells (CBNK)
 

AB-101 is an allogeneic NK cell product derived from US-sourced healthy donor, licensed Umbilical Cord Blood (UCB) selected for key anti-tumor characteristics including KIR-B haplotype and homozygous F158V/V CD16 polymorphism. The proprietary manufacturing procedure results in highly active NK cells primed for anti-tumor activity and optimized for use in combination with monoclonal antibody therapy; with extremely high and consistent expression of natural high-affinity CD16. 1000s of doses of pure, cryopreserved, infusion-ready NK cells can be generated from a single UCB and drug product is extremely consistent from donor-to-donor.

 

AB-101 is for therapeutic use in combination with monoclonal antibody therapy and is planned to enter clinical assessment in Q3 2020. Its first clinical application is in relapsed refractory B-cell lymphoma in combination with anti-CD20 monoclonal therapy.

 

AB-201 is a CAR-NK product targeting Her2 positive solid tumors. The CAR construct has been optimized for activity within NK cells and utilizes a highly specific proprietary anti-Her2 extracellular domain. The background NK cells maintain all the preferred characteristics seen within the AB-101 product, including high expression of activating NK receptors and CD16 as well as the cryopreservation and infusion-ready formulation.

The first clinical studies with AB-201 are planned for mid-2020 and include an assessment of activity in several Her2+ solid tumor types.

 
 

AB-202 is a CAR-NK product targeting CD19 positive hematopoietic malignancy. The CAR construct has been optimized for activity within NK cells and utilizes a highly specific anti-CD19 extracellular domain. The background NK cells maintain all the preferred characteristics seen in the AB-101 product, including high expression of activating NK receptors and CD16 as well as the cryopreservation and infusion-ready formulation.

The first clinical studies with AB-202 are planned for the second half of 2020 and include an assessment dual tumor-antigen targeting via combination therapy with anti-CD20 monoclonal therapy.

Information on partnering; technologies that can be incorporated into product. 

Sign up for news updates

  • Twitter
  • LinkedIn

Privacy Policy  |  Terms
© Artiva Biotherapeutics, Inc., 2020